India’s Advinus Signs On With Genzyme In Malaria Research
This article was originally published in PharmAsia News
Executive Summary
Anti-malarial drug research involving Genzyme and others is set to expand with the help of new Indian partner Advinus, just taken on board to develop early-stage candidates
You may also be interested in...
Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 2 of 2)
Genzyme CEO Henri A. Termeer, has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.
Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 2 of 2)
Genzyme CEO Henri A. Termeer, has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.
Genzyme Firms Up Long Term, High Investment Plans For India
MUMBAI - U.S. biotech Genzyme has firmed up a long-term, high-investment growth plan for India. The plan includes launch of Genzyme's entire portfolio of 15 drugs over the next three to four years, forging partnerships for research on drugs that are relevant to India, devising access programs and expanding scope of clinical trials on its experimental drugs